Follow us on Twitter
twitter icon@FreshPatents


Proliferative patents

      

This page is updated frequently with new Proliferative-related patent applications.




 Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease patent thumbnailChimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore


 Substituted tetrahydropyridothienopyrimidines patent thumbnailSubstituted tetrahydropyridothienopyrimidines
The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. .
Bayer Pharma Aktiengesellschaft


 Pyridyl piperidines patent thumbnailPyridyl piperidines
The invention provides novel substituted pyridyl piperidine compounds according to formula (i) which are wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.. .
Cancer Research Technology Limited


 Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications ofantitumor thereof patent thumbnailSubstituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications ofantitumor thereof
Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (i) as akt inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of r1, r2, r3, r4, r5, r6, ring a, ring c, b, q, y, z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to akt kinase..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


 Novel compounds patent thumbnailNovel compounds
The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.. .
Bayer Pharma Aktiengesellschaft


 Pyridyl benzothiophenes as kinase inhibitors patent thumbnailPyridyl benzothiophenes as kinase inhibitors
This invention is directed to compounds, which are useful as protein kinase (pk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.. .
Allergan, Inc.


 Combination therapy with thiocolchicine derivatives patent thumbnailCombination therapy with thiocolchicine derivatives
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a colchicine or thiocolchicine dimer and an anti-vegf antibody. The method may further comprise administering an effective amount of a taxane.
Abraxis Bioscience, Llc


 Thienopyranones as kinase and epigenetic inhibitors patent thumbnailThienopyranones as kinase and epigenetic inhibitors
The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.


 Pyridone compounds, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases patent thumbnailPyridone compounds, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
Provided herein are pyridone compounds, for example, a compound of formula i, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease..
Biotheryx, Inc.


 Regulators of anaplastic lymphoma kinase and uses thereof patent thumbnailRegulators of anaplastic lymphoma kinase and uses thereof
Provided herein are alk regulators for the treatment of diseases and disorders. For example, presented herein are alk regulators, e.g., alk activators, and methods of treatment and/or prevention of diseases, including neurodegenerative, neuromuscular and cognitive diseases or disorders, and methods of enhancing cognitive abilities using alk regulators, e.g., alk activators.
Yale University


Combinations of an fgfr inhibitor and an igf1r inhibitor

The invention relates to a combination of a fgfr inhibitor and an igf1r inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer.
Astex Therapeutics Ltd

Hspc-sparing treatments for rb-positive abnormal cellular proliferation

This invention is in the area of improved compounds for and methods of treating selected rb-positive cancers and other rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy hematopoietic stem cells and progenitor cells (hspcs), associated with current treatment modalities. In one aspect, improved treatment of select rb-positive cancers is disclosed using specific compounds disclosed herein.
G1 Therapeutics, Inc.

Compositions and methods for cancer therapy

The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (edta) to form h2o2, and one or more anti-cancer therapies.. .
University Of Iowa Research Foundation

Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors

Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4 and x are as defined herein. The compounds of formula i are useful as receptor tyrosine kinase (rtk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases..

Dvdms sensitizer for cancer sonodynamic therapy

A method for treatment of hyperproliferative tissue by injection of and subsequently exposing the hyperproliferative tissue to a frequency of ultrasound. The invention further includes purified bis [1-[6,7-bis [2-(sodium carbonate ethyl]-1,3,5,8,-tetramethyl-2-vinyl-porphin-4-yl]ethyl]ether (dvdms) for use in sonodynamic treatment of hyperproliferative tissue including cancer and further includes a kit including a dosage controllable injection device charged with a biologically compatible fluid containing dvdms..

Methods for treating cancer with a wee1 inhibitor

The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a wee1 inhibitor. The presence or absence of a mutation to the tp53 gene, can be used to predict response to treatment with a wee1 inhibitor in a patient presenting with a cancerous condition..
Merck Sharp & Dohme Corp.

Combination therapy to enhance the anticancer efficacy of platinum drugs

The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death. It is based, at least in part, on the discovery that in platinum drug-resistant cell lines, certain compounds, together with a second antiproliferative agent (e.g., cisplatin), act synergistically to promote apoptosis.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Combination therapy with glutaminase inhibitors and immuno-oncology agents

The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, ctla-4, indoleamine 2,3-dioxygenase, and/or pd-1/pd-l1.. .
Calithera Biosciences, Inc.

Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (pi3k) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mtor) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mtor) kinase dependent diseases.. .
Novartis Ag

Monoclonal antibodies to programmed death 1 (pd-1)

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.

Ocular formulations

Compositions and methods for providing anesthesia to the eye, for treating or preventing inflammatory disorders in the eye, or for treating or preventing ocular infections, are disclosed. The compositions include a glycosaminoglycan, such as hyaluronic acid, in a concentration suitable for achieving a desired viscosity, as well as an active agent, such as an anesthetic, anti-inflammatory, antimicrobial, antiproliferative, antimetabolite, prostaglandin, antioxidant, tgf-beta, or mitomycin c..
Encompass Development, Inc.

Novel modulators and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.. .
Abbvie Stemcentrx Llc

Treatment of inflammatory skin disorders

The invention relates to methods of using an effective amount of activated protein c (apc) to treat an individual for a skin disorder characterised by the presence of hyperproliferative keratinocytes.. .
Zz Biotech Llc

Compositions and methods relating to proliferative diseases

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described.
The Penn State Research Foundation

Antagonists of slc38a9 and their use in therapy

The present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh

Compositions and methods for anti-lyst immunomodulation

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital

Heteroaryls and uses thereof

And pharmaceutically acceptable salts thereof, wherein x, r1, r2, r3, r4, r5, l1, l2, m, and n, are as described in the specification. Such compounds are inhibitors of vps34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders..

Suprametallogels and uses thereof

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology

Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of janus kinases and are useful in the treatment of diseases related to activity of janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.. .
Incyte Holdings Corporation

Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders

The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients..
Epigenomics Ag

Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders

The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients..
Epigenomics Ag

A producing an adult-type oligodendrocyte

The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult opc produced according to that method. The method for producing adult opc of the present invention is characterized by inducing proliferating opc to differentiate into adult opc by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment.
Japan Science And Technology Agency

Alpha3beta hydrogen bond surrogate macrocycles as modulators of ras

The present invention relates to peptides having a stable, internally-constrained hbs α-helix, where the peptide mimics at least a portion of the α-h helix of the sos protein and contains a mixture of alpha and beta amino acid residues in the pattern α3/β1. Methods using the peptides of the present invention for inhibiting ras signaling in a cell, promoting cell death, and treating, preventing, and/or diagnosing a cellular proliferative disorder, differentiative disorder, and/or neoplastic condition in a subject in need thereof are also disclosed..
New York University

Withaferin a analogs and uses thereof

The present invention provides a novel class of withanolides that have been isolated from w. Somnifera under aeroponic conditions or produced semi-synthetically from withanolide natural products.
Arizona Board Of Regents On Behalf Of The University Of Arizona

[1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as taz compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit axl receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit axl receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by axl receptor tyrosine kinase, that are ameliorated by the inhibition of axl receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc..
Cancer Research Technology Limited



Proliferative topics:
  • Proliferative
  • Proliferative Disorder
  • Pharmaceutically Acceptable Salt
  • Antagonist
  • Recurrence
  • Antibodies
  • Extracellular
  • Osteochondrosis
  • Reproduction
  • Somatic Cell
  • Metalloprotein
  • Pharmaceutically Acceptable Salts
  • Pyrimidine
  • Immune Disorder
  • Immune Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Proliferative for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Proliferative with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3284

    file did exist - 2688

    1 - 1 - 52